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RESEARCH ARTICLE
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Abstract
The TGF-b superfamily cytokine MIC-1/GDF15 circulates in the blood of healthy humans.
Its levels rise substantially in cancer and other diseases and this may sometimes lead to
development of an anorexia/cachexia syndrome. This is mediated by a direct action of MIC-
1/GDF15 on feeding centres in the hypothalamus and brainstem. More recent studies in
germline gene deleted mice also suggest that this cytokine may play a role in physiological
regulation of energy homeostasis. To further characterize the role of MIC-1/GDF15 in physi-
ological regulation of energy homeostasis in man, we have examined diurnal and food
associated variation in serum levels and whether variation in circulating levels relate to BMI
in human monozygotic twin pairs. We found that the within twin pair differences in serum
MIC-1/GDF15 levels were significantly correlated with within twin pair differences in BMI,
suggesting a role for MIC-1/GDF15 in the regulation of energy balance in man. MIC-1/
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GDF15 serum levels altered slightly in response to a meal, but comparison with variation its
serum levels over a 24hour period suggested that these changes are likely to be due to
bimodal diurnal variation which can alter serum MIC-1/GDF15 levels by about plus or minus
10% from the mesor. The lack of a rapid and substantial postprandial increase in MIC-1/
GDF15 serum levels suggests that MIC1/GDF15 is unlikely to act as a satiety factor. Taken
together, our findings suggest that MIC-1/GDF15 may be a physiological regulator of energy
homeostasis in man, most probably due to actions on long-term regulation of energy
homeostasis.
Introduction
The regulation of food intake, energy storage and energy expenditure is tightly controlled by
complex homeostatic mechanisms. Total body nutritional and energy status, as well as the
nutritional status in the gut lumen and circulation, is conveyed to the central nervous system
(CNS), in large part via the release of hormones from the gut, pancreas and adipose tissue. The
CNS, in turn, initiates the transcription and release of neuropeptides in the hypothalamus and
brainstem, which then modulate feeding and metabolism to maintain energy homeostasis [1–
3]. Gut- and adipose tissue-derived hormones may increase or decrease appetite. Satiety induc-
ing gut hormones include cholecystokinin (CCK), amylin, glucagon-like peptide-1 (GLP-1),
pancreatic polypeptide (PP) and peptide YY (PYY), which are released in response to food
intake and act over short time frames [4]. Longer term appetite regulation involves mediators
such as insulin from the pancreas, and leptin from fat [5]. In disease states, other regulatory
molecules have also been identified as regulating energy homeostasis, raising the possibility
that some of them may also be involved in physiological regulation of energy homeostasis. One
such molecule is macrophage inhibitory cytokine/growth differentiation factor 15 (MIC-1/
GDF15) [6], an unusual and divergent member of the TGF-b superfamily, also known as
GDF15, PLAB, NAG-1 or PTGFB [6–8]. We have previously demonstrated that elevated circu-
lating levels of this cytokine in disease states are an important cause of the anorexia/cachexia of
cancer and other diseases [9].
MIC-1/GDF15 is a stress response cytokine that plays a role in several biological processes
including cancer, chronic inflammatory diseases and energy homeostasis (reviewed in [10,
11]). The major source of circulating MIC-1/GDF15 is uncertain, but is probably the liver,
although it is also expressed in other tissues including kidney, lung and adipose tissue. To exert
a biological effect, MIC-1/GDF15 must activate its cognate receptor complex, which to this
point has not been definitively identified. However, its receptor chains are likely to belong to
the highly conserved heterodimeric TGF-b receptor (TBR) superfamily. There is some evidence
for involvement of TBRII [12, 13], but as yet there is no genetic or direct biochemical data to
confirm this and for this reasons its downstream signaling has not yet been clearly elucidated.
Many different types of cancers express MIC-1/GDF15 causing elevation in its circulating lev-
els [14–17]. In advanced cancers, serumMIC-1/GDF15 levels can rise dramatically, from the
normal mean of about 450 pg/mL to 10,000–100,000 pg/mL [8, 14]. Elevated serumMIC-1/
GDF15 levels have been linked to anorexia/cachexia associated with cancer [9], chronic renal
[9] and cardiac failure [18, 19].
In experimental animals, MIC-1/GDF15 levels of above 5,000–8,000 pg/mL cause severe
anorexia/cachexia [9] because of actions on feeding centres in the brainstem and hypothalamus
[9, 20]. However, MIC-1/GDF15 is normally present in the blood of normal adult humans,
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with a broad normal range of 150 to 1150 pg/mL [16], which may rise substantially further in
the elderly [21, 22]. This raises questions as to whether MIC-1/GDF15 levels within this normal
circulating range may also regulate energy homeostasis. In support of this, our previous data
demonstrated that MIC-1/GDF15 germline knockout mice (MIC-1-/-) have significantly
increased visceral abdominal fat mass and weighed more than their syngeneic controls with a
more pronounced obese phenotype in female than in male mice. Female MIC-1-/- mice also ate
significantly more and exhibited reduced basal energy expenditure. Moreover, when MIC-1-/-
mice were infused with sufficient recombinant MIC-1/GDF15 to raise their serum levels to the
middle of the normal human range, their body weight and food intake were significantly
reduced. These findings suggested that, at least in mice, physiological concentrations of MIC-
1/GDF15 play a role in the regulation of appetite, fat deposition and body weight [23, 24].
To investigate whether MIC-1/GDF15 may also play a role in the regulation of energy
homeostasis in humans, this study examined the relationship between body mass index (BMI)
and serumMIC-1/GDF15 levels in a cohort of elderly identical twins. Additionally, circulating
levels of MIC-1/GDF15 after ingestion of a high-energy meal were compared with the diurnal
change in serumMIC-1/GDF15 levels. Lastly, interactions between MIC-1/GDF15 and several
currently known gut-derived satiety factors were examined in healthy men.
Materials and Methods
Quantification of serumMIC-1/GDF15 levels
Collected serum or plasma samples were assayed for human MIC-1/GDF15 using a previously
described, in house ELISA [25, 26].
Ethics statement
All study participants provided written informed consent at the time of study enrollment and
was approved by the relevant ethics committees.
Human twin studies. The ethics committees at Karolinska Institute and Umeå University
approved the studies [22].
Circadian serum levels of MIC-1/GDF15. Institutional ethic committee of Shanghai Jiao
Tong University approved the study protocol [27].
Fasting-refeeding studies in men. Sample collection was carried out at the Department of
Human Nutrition, Faculty of Life Sciences, University of Copenhagen, Frederiksberg, Den-
mark, and was approved by the Municipal Ethical Commmittee of Copenhagen and Frederik-
berg in accordance with Helsiniki-II declaration (KF01-144/02) [28].
CCK and GLP infusion studies in men. The Royal Adelaide Hospital Ethic Committee
approved the study protocol [29].
PYY infusion studies in men. The Ethics and Radiation protection committees of the
Karolinska University Hospital, Sweden, approved the study [30].
Human twin studies
The twin cohort has been previously described in several studies [22, 31, 32]. For the purpose
of this study, the analysis was performed with serum from a group of 72 monozygotic non-
obese twin-pairs. These were identified from the Swedish Twin Registry and had accessible
serum samples, BMI data and self-reported life-style habits. Zygosity had been previously con-
firmed by either restriction fragment length polymorphism or serological testing. The twin
pairs were aged between 63–93 years of age and had a BMI less than 30 kg/m2, and 69% of the
pairs were female.
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Diurnal serum levels of MIC-1/GDF15
The diurnal pattern of serumMIC-1/GDF15 levels was determined in a cohort of 14 healthy
men (n = 6) and women (n = 8) of Asian background and aged between 20 and 40 years, with a
BMI ranging from 18 to 25 kg/m2. The serum samples from this cohort have been used in
another study [27]. Briefly, all the subjects were housed in a ward of the Shanghai Sixth Hospi-
tal where they were allowed to freely walk around the ward, but not allowed to undertake stren-
uous activities. The lights were switched off during their sleep period of about 11:00 pm to 7:00
am. Subjects were provided with a standardized dinner at 1700 hours and were then fasted for
24 hours with free access only to water, from 1800 hours until 1800 hours on the following day.
Blood samples were taken every 30 minutes during the period of fasting, from 1800 on day 1 to
1800 on day 2.
Fasting-refeeding studies in men
Changes in serumMIC-1/GDF15 levels after fasting and following meal ingestion were deter-
mined in a cohort of 17 healthy male subjects aged between 18 and 50 years, with a BMI rang-
ing from 24 to 31 kg/m2. The serum samples from this cohort have been used in another study
and the experimental design has been previously described [28]. The study was approved by
the Municipal Ethical Committee of Copenhagen and Frederiksberg, Denmark. Briefly, on the
evening before commencement of the experiment, subjects were given a standardized meal to
consume at no later than 2000 hours. They were not allowed to eat after that time, but were
instructed to drink 0.25 L of water both before bed and in the morning before leaving their
home. The subjects were instructed to avoid any heavy strenuous activities and alcohol 48 h
before each test day. On the day of the experiment, subjects were provided with one of five iso-
caloric test meals, and these 5 meals were tested in these 17 subjects on 5 separate days in a ran-
domized order. All test meals contained the same macronutrient composition with same
portion of energy from protein (15%, casein powder + whey powder), fat (39%) and carbohy-
drate (46%), the differences between the meals are significant variations in mineral content:
either high, medium or low amounts of calcium. The fourth meal contained low amount of cal-
cium from dairy products and a calcium supplement served as a drink containing calcium car-
bonate. The fifth test meal contained soy protein powder as the only source of dairy protein
and a low amount of calcium from dairy product. Each subject received portions that were
matched to their individual energy requirements, which were determined using a formula
based on a meta-analysis of 24-h calorimetry studies [28]. Each test meal contained 50% of the
subject’s daily energy requirements. Blood samples were collected at 0, 30, 60, 90, 120, 180, 300
and 420 minutes after food intake.
CCK and GLP infusion studies in men
The cohort used for this study has been previously described [29]. Briefly, this comprised 9
healthy male subjects aged between 18–27 years with a BMI between 20–25.2 kg/m2. After fast-
ing overnight the subjects received intravenous infusions of isotonic saline, CCK-8 (1.8 pmol/
kg/min) or GLP-1 (0.9 pmol/kg/min) or CCK plus GLP-1 at the same doses, in randomized,
double-blind fashion on four different days separated by at least 3–10 days. The duration of the
infusions was 150 minutes, and at t = 120 minutes, subjects were offered a standardized, cold
buffet-style meal [29]. Subjects were allowed 30 min to consume the meal until they felt com-
fortably full. Blood samples were collected at 10-minute intervals for the first 30 minutes, at
15-minute intervals for the next 30 minutes, and at 30-minute intervals for the remaining 1200
minutes.
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PYY infusion studies in men
This cohort has been previously described [30]. Briefly, it comprised 8 healthy subjects (4 men,
4 women; age 28 ± 4 years; BMI 22 ± 2 kg/m2). Subjects were fasted overnight followed by
ingestion of a 310 kcal egg omelet and a 70 kcal soft drink. This comprised energy from fat
(57%), protein (22%), and carbohydrate (21%). On three different and separate study occa-
sions, subjects received infusion of either 0.8 pmol/kg/min synthetic human PYY1-36 or
PYY3-36 in 0.9% saline containing 0.1% albumin, or control (0.9 saline containing 0.1% albu-
min). Infusions started simultaneously with the meal intake and continued for 180 minutes.
Blood samples were collected at 10-minute intervals for the first 60 minutes, followed by sam-
ples collected at 120 and 180 minutes.
Statistics
All analyses were performed using GraphPad Prism (PRISM 4, GraphPad, San Diego, CA). In
the twin cohort study, within-pair differences in BMI and MIC-1/GDF15 serum level were
determined. These differences were plotted against each other and the correlation was analysed
using Spearman regression, as data were not parametric.
For experiments studying postprandial serum levels of MIC-1/GDF15, measurements were
obtained from 17 subjects that had 5 different meals on 5 separate occasions. The averages of
MIC-1/GDF15 serum level from all subjects between 5 meals were compared by two-way
repeated measure ANOVA. The average of the serumMIC-1/GDF15 level from the 5 meals
were combined and then further analysed with a one-way ANOVA for time dependent interac-
tion. Data from cohorts infused with CCK, GLP, or PYY were analysed by two-way repeated
measures ANOVA with Bonferroni correction for multiple comparisons. Results are presented
as means ± s.e.m. For all statistical tests, p values< 0.05 were considered to be statistically
significant.
The diurnal rhythm of serumMIC-1/GDF15 levels for the ith subject was modeled by the
equation
LiðtÞ þ εiðtÞ ¼ ai cos
2p
24
t þ i
 
þ bi
Here Li(t) is the level of MIC at time t, αi, ϕi and bi are constants, and εi(t), the error in the mea-
surement, is a zero mean Gaussian noise. Each individual time series is ﬁt to this function. The
ﬁts were performed using “NonlinearModelFit” in Mathematica. The model assumed Nor-
mally distributed error terms, so the residuals were tested to see if they were Normal. To a sig-
niﬁcance of 0.05, the residuals from all but subjects 11, 12, and 14 were Normally distributed.
In the latter subjects, the presence of a small number of large outliers was responsible for this
ﬁnding.
To test whether acrophase times are clustered, we performed Kuiper’s test [33] against the
hypothesis that the maxima occur at random times between 0 and 24 hours. The resulting test
statistic was 0.506, which gives a p-value of 0.00094, hence the null hypothesis that the acro-
phase times are distributed according to a uniform distribution is rejected at the 0.05 level.
Results
Human MIC-1/GDF15 serum levels are inversely correlated with BMI
To investigate whether MIC-1/GDF15 may regulate energy homeostasis in humans, as in mice,
we examined the relationship between MIC-1/GDF15 serum levels and BMI. To increase the
sensitivity of our analysis we examined genetically identical, non-obese monozygous twins
Diurnal Effect of MIC-1/GDF15 in Man
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from the Swedish twin cohort [21, 22, 31] with the aim of eliminating the effect of heritable var-
iables and reducing disease-related confounding factors. The within-pair difference in serum
MIC-1/GFDF15 levels was inversely correlated with the within-pair difference in BMI (n = 72
twin pairs, r = 0.426 and p = 0.0016) (Fig 1). For example, this means that when one twin had a
higher serum MIC-1/GDF15 level than his/her identical sibling, the BMI was generally lower
than that of the sibling. The reverse was also true. These data suggest that in non-obese human
subjects, MIC-1/GDF15 may regulate BMI independently of genetic background. Furthermore,
the observed correlation between MIC-1/GDF15 serum levels and BMI in humans suggests
that the data we have previously obtained in mice, demonstrating that high MIC-1/GDF15 lev-
els lead to weight loss and that absent MIC-1/GDF15 levels leads to weight gain[23], may also
apply to humans.
Human MIC-1/GDF15 serum levels are modulated in a diurnal pattern
To determine whether circulating MIC-1/GDF15 is subject to diurnal variation, we studied an
Asian cohort from whom blood was drawn periodically over a single 24-hour cycle [27] and
analyzed for serumMIC-1/GDF15 (Fig 2 and Table 1). These data indicate a biphasic pattern
of serumMIC-1/GDF15 over 24 hours, with a mean serum level of 387.0 ± 4.2 pg/mL. For 12
of the 14 subjects, circulating MIC-1/GDF15 levels showed a diurnal variation with a peak
around midnight and a nadir approximately at noon. The remaining two subjects (subjects 3
and 10, Fig 2 and Table 1) also show a diurnal variation, however, these cycles are out of phase
with the majority (by 8 and 14 hours, respectively). For each subject, the diurnal variation in
Fig 1. Correlation of monozygotic within-pair differences in MIC-1/GDF15 serum levels and within-pair
differences in BMI. Correlation between within twin-pair difference in serumMIC-1/GDF15 levels and within
twin-pair difference in BMI (n = 72 twins), performed by Spearman regression, identifies a highly significant
correlation. In general the twin of the twin pair with a higher serumMIC-1/GDF15 level generally had a lower
BMI than their identical twin pair. The reverse was also true.
doi:10.1371/journal.pone.0133362.g001
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Fig 2. Fasting diurnal variation of humanMIC-1/GDF15 serum levels. SerumMIC-1/GDF15 levels were
measured on blood sample taken from participants every 30min during a 24h period. The oscillatory pattern
of serumMIC-1/GDF15 levels for each individual subject was fitted to a cosine curve function.
doi:10.1371/journal.pone.0133362.g002
Diurnal Effect of MIC-1/GDF15 in Man
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serumMIC-1/GDF15 serum levels could be fitted to a cosine curve (see Methods) and the
acrophase times were clustered rather than occurring at random times over the 24 hour cycle
(Kuiper’s test 0.506; p<0.0001). For the 12 subjects that are approximately in phase, the acro-
phase (clock time of maximal value) occurred at 0022 h (standard deviation of 1 hr 48 minutes)
and the nadir at 1222 h (standard deviation of 1 hr 48 minutes). For these subjects, circulating
MIC-1/GDF15 levels reach a peak of 422 ± 15 pg/mL at acrophase, and a minimum value of
341 ± 17 pg/mL at the nadir (Fig 2 and Table 1). The 24-hour cosine amplitude (half of the
peak-nadir difference) was 381 ± 41 pg/mL, and the MESOR (midline estimating statistic of
rhythm) was 381 ± 15 pg/mL. Thus, this diurnal oscillation leads to a variation in circulating
MIC-1/GDF15 concentration about the MESOR of about ± 10%.
Postprandial changes of human MIC-1/GDF15 serum levels are not
significantly different from its diurnal variation
One mechanism by which MIC-1/GDF15 might influence body weight and food intake is by
promoting satiety. If this were the case, food intake might lead to a substantial rise in serum
MIC-1/GDF15 levels. To evaluate this, circulating MIC-1/GDF15 levels were measured in a
fasting refeeding cohort in which samples were drawn between 0900 and 1600 h of day. The
average response of the 17 subjects to all 5 different meals showed a similar pattern of post-
prandial serum MIC-1/GDF15 levels over time, which did not vary significantly between the 5
meals (Fig 3A; p = 0.26). On average for the 5 different meals (Fig 3B), MIC-1/GDF15 serum
concentrations decreased to a minimum of 92.2 ± 0.7% of fasting levels at 30 to 60 minutes
post meal (0 vs 30 minutes or 60 minutes, p< 0.01). It then rose to peak at 108.9 ± 2.1% of fast-
ing levels at 120 minutes post meal (90 vs 120 minutes, p< 0.01), after which it dropped to
102.6 ± 1.1% at 180 and 300 minutes post meal, which was not significantly different from the
fasting concentration (0 versus 180 min or 300 minutes, p> 0.06). MIC-1/GDF15 serum con-
centrations, then increased significantly to 113 ± 0.7% of fasting values at 420 minutes post
meal (300 versus 420 minutes, p< 0.001).
These undulating changes in serumMIC-1/GDF15 concentrations in the 7 hours after a
meal made us question whether the changes in concentrations were due to the meal itself, or
due to an underlying diurnal variation. Indeed, comparison of serum MIC-1/GDF15 level
Table 1. Time of day for maximum andminimumMIC-1/GDF15 serum levels.
Subject Time of Maximum Time of Minimum
1 00:40 12:40
2 22:36 10:36
3 07:53 19:53
4 01:57 13:57
5 03:44 15:44
6 01:36 13:36
7 22:29 11:45
8 01:22 13:22
9 23:45 11:45
10 14:21 02:21
11 00:11 12:11
12 01:03 13:03
13 00:04 12:04
14 20:57 08:57
doi:10.1371/journal.pone.0133362.t001
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between the postprandial fasting refeeding cohort with samples from the diurnal cohort, col-
lected fasting (13–20 hours after feeding) and at the same time of the day (0900 to 1600 h;
Fig 3C) were very similar. A gradual rise in serum MIC-1/GDF15 concentrations was observed
from 1000 h in both groups of subjects, and these patterns were not significantly different from
each other (meal  fasting: p = 0.28, repeated measures ANOVA). This result shows that
although there are small changes in MIC-1/GDF15 concentration in the hours after food
intake, these could at least in part be accounted for by the underlying diurnal variation pattern.
Effect of CCK and GLP-1 infusion on serum levels of MIC-1/GDF15
To evaluate whether circulating satiety hormones might modulate serumMIC-1/GDF15, we
measured its levels in subjects who were infused intravenously with either vehicle, CCK-8,
GLP-1, or CCK-8 plus GLP-1. For comparison purposes the serumMIC-1/GDF15 level for
Fig 3. Postprandial changes in humanMIC-1/GDF15 serum levels.Changes in serumMIC-1/GDF15 levels over time were measured in 17 subjects that
received 5 different isocaloric meals on 5 separate occasions. (A) Changes in MIC-1/GDF15 serum levels do not differ for the 5 subjects fed the 5 different
meals (n = 17, p = 0.26 repeated measure ANOVA). (B) When average data from all meals was pooled and normalised to baseline concentrations, there was
significant time dependent alteration in circulating MIC-1/GDF15 levels (n = 5 meal; 17 subject/meal, p < 0.001 one-way ANOVA). (C) The postprandial
profile of MIC-1/GDF15 serum levels (red) described in panel B were not significantly from its 24 h oscillatory pattern (p = 0.28, repeated measure ANOVA).
Data represented as mean ± s.e.m.
doi:10.1371/journal.pone.0133362.g003
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each participant was normalized to the value obtained at time zero (Fig 4). Compared to vehi-
cle, subjects receiving CCK-8 infusion alone exhibited a small, but significant, time dependent
increase in serum levels of MIC-1/GDF15 (treatment  time: p = 0.001, repeated measures
ANOVA, Fig 4A). This change was particularly notable after consumption of the buffet meal,
because a significant increase in circulating MIC-1/GDF15 levels was found at 120, 150 and
180 minutes after commencement of CCK-8 infusion (vehicle versus CCK, n = 8; 120 min;
p = 0.05, 150 min; p = 0.01, 180 min; p< 0.001 repeated measure ANOVA with Bonferroni
correction for multiple testing). MIC-1/GDF15 serum levels were not modulated by GLP-1
infusion alone (vehicle versus GLP-1, treatment p = 0.6; treatment  time, p = 0.2, repeated
measures ANOVA), nor did CCK plus GLP-1 have any significant effect on serum levels of
MIC-1/GDF15 (vehicle versus CCK-8 + GLP-1, treatment, p = 0.36; treatment  time, p = 0.06,
repeated measure ANOVA). The CCK8 infusion associated changes in MIC-1/GDF15 serum
levels are very small, not likely to be biologically significant and may be well accounted for by
the underlying diurnal variation.
Effect of PYY infusion on serum levels of MIC-1/GDF15
To ascertain whether the satiety factor PYY may modulate MIC-1/GDF15, we measured its
serum levels in healthy subjects infused with vehicle, PYY1-36 or PYY3-36 on 3 separate occa-
sions. For comparison purposes the serumMIC-1/GDF15 level for each person was normal-
ized to the value obtained at time zero. Infusion of the full length PYY (PYY1-36) had no
significant effect on serumMIC-1/GDF15 concentrations (n = 8, vehicle versus PYY1-36, treat-
ment, p = 0.18; treatment  time, p = 0.18, repeated measures ANOVA) (Fig 4B). Similarly,
infusion of the truncated PYY (PYY3-36) had no effect on the serum levels of MIC-1/GDF15
(vehicle versus PYY3-36, treatment, p = 0.34; treatment  time, p = 0.4, repeated measures
ANOVA). These findings suggest that neither PYY1-36 nor PYY3-36 has a significant effect on
serum levels of MIC-1/GDF15.
Fig 4. Effect of satiety factor infusions on serum levels of humanMIC-1/GDF15. (A) Subjects receiving CCK-8 infusion alone had significant time
dependent increase in serum levels of MIC-1/GDF15 with significant increases at 120, 150 and 180 minutes of infusion. Infusion of GLP-1 or CCK plus GLP-1
had no significant effect on serumMIC-1/GDF15 level (n = 9, vehicle vs GLP-1, p = 0.2; vehicle vs CCK-8 + GLP-1, p = 0.06). (B) PYY1-36 or PYY3-36 or
saline was infused in subjects that were fasted overnight and had a 310-Kcal meal. Neither PYY1-36 nor PYY3-36 infusions had a significant effect on serum
MIC-1/GDF15 levels (n = 8, vehicle vs PYY1-36, p = 0.18; vehicle vs PYY3-36, p = 0.34). Data were analysed by ANOVAwith Bonferroni correction and are
presented as mean ± s.e.m. * represents p < 0.05.
doi:10.1371/journal.pone.0133362.g004
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Discussion
This study provides the first evidence that circulating concentrations of MIC-1/GDF15 vary in
a diurnal pattern. Further, consistent with our animal data [23], there was a significant correla-
tion between its serum concentrations and BMI in monozygotic twin pairs, suggesting that it
may also have a physiological role in the regulation of energy homeostasis in humans. Since we
could not identify any direct evidence for the substantial postprandial changes in MIC-1/
GDF15 serum level, we suggest that MIC-1/GDF15 is unlikely to be a satiety factor and is most
likely to regulate long term energy balance.
Our previous studies of MIC-1/GDF15’s role in energy homeostasis under physiological
conditions, have been undertaken in mice. Studies in inbred mouse lines including transgenic
and gene knockout mice allow us to control for the major changes that can occur because of
genetic variations between individuals. In humans, the best way to control for genetic varia-
tions is to study monozygotic twins. In this study we have been able to capitalize on the genetic
identity of monozygotic twins, but at the same time, utilize the small phenotypic differences in
BMI that develop within non-obese twin pairs, to show that there is a significant relationship
between the within-pair difference in serum levels of MIC-1/GDF15 and the within-pair differ-
ence in BMI such that the twin of the twin pair with the higher MIC-1/GDF15 serum level usu-
ally has the lower BMI and visa versa. One limitation in this sub study is a relative lack of data
regarding health status in twins that might influence serumMIC-1/GDF15 levels. However, as
we, and others, have shown, significant relationships with circulating MIC-1/GDF15 levels and
BMI in a range of diseases [9, 14, 34–36], in this context, we do not believe it is a major limita-
tion. Therefore, independent of heritable factors, the consistent data between humans and
mice suggests that MIC-1/GDF15 has a conserved role in regulating body weight.
It is common for serum levels of cytokines, such as IL-6 and TNF-alpha, to rise with age
and MIC-1/GDF15 are not an exception. Its serum levels are significantly higher in elderly
cohorts like ours [22, 34] [37] and aging itself seems to be the major non-genetic contributing
factor associated with elevated serum MIC-1/GDF15 [14, 37]. A previous study performed in
the same monozygotic twin cohort [22] showed that unique rather than shared environmental
factors might influence serumMIC-1/GDF15, and these environmental factors may be those
associated with ageing such as oxidative stress or elevation of levels of other cytokines.
Our studies have also identified that in line with many metabolic modulators, serum levels
of MIC-1/GDF15 vary in a bimodal diurnal pattern. In humans of Asian background, we
found that the 24-hour profile of circulating MIC-1/GDF15 levels show a trough in concentra-
tion occurring at about 1222 h and a peak in concentration occurring at around 0022 h. Fasting
and then refeeding at 0900 h does not significantly modify this pattern (Fig 3). However, it is
possible that some of this diurnal variation is entrained to meal patterns, as has been noted for
circulating levels of energy regulatory hormones, such as leptin [38]. Therefore, additional
diurnal profiling of circulating MIC-1/GDF15 after prolonged fasting would be needed to
determine if its diurnal profile is entrained to meal patterns or follows an independent circa-
dian pattern. Interestingly, a similar diurnal pattern to that of MIC-1/GDF15 has been previ-
ously observed for leptin [39, 40], in which the highest circulating levels were reached after
midnight, and the nadir occurred at around noon. However, the nocturnal rise in circulating
leptin was totally eliminated in subjects fasted for 72 hours prior to sample collection [41],
indicating that the rhythm in daily leptin concentrations was entrained by meals. The noctur-
nal rise in MIC-1/GDF15 seen in the current study also resembles the rise in growth hormone
(GH) secretion and the increase in circulating free fatty acids (FFAs) that have been seen in
other publications [40]. Interestingly, GH secretion is known to profoundly affect body compo-
sition, and as body composition is a phenotypic change in MIC-1-/- mice [23], it is conceivable
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that there is a relationship between the secretion of MIC-1/GDF15, leptin and GH. This is fur-
ther supported by an earlier study showing that mice bearing MIC-1/GDF15 overexpressing
tumors have reduced hypothalamic expression of mRNA for growth hormone releasing hor-
mone (GHRH) [9].
The area postrema (AP) and nucleus of the solitary tract (NTS) in the hindbrain are crucial
regions for the anorexigenic actions of MIC-1/GDF15 [20]. These regions are also major sites
of action for satiety factors such as CCK-8, GLP-1 and PYY. For example, the CCK-1 (or, A)
receptor is expressed in these regions, as well as in the dorsal medial hypothalamus (DMV)
and in the vagal afferent neurons of the stomach and small intestine [42, 43]. One of the major
characteristics of these satiety factors is that their circulating levels are rapidly and substantially
elevated post-prandially, due to food-induced secretion from the gastrointestinal tract. For
example, both PYY and GLP-1 are expressed by the intestinal endocrine cells and are rapidly
released into the circulation after a meal. Based on this parallel between the central sites of
action of MIC-1/GDF15 and known satiety hormones, it seemed plausible that MIC-1/GDF15
might have satiety factor-like activity. Whilst we did not test directly for satiety factor activity
of MIC-1/GDF15, we would expect to observe a rapid and substantial postprandial variation in
its serum levels similar to that seen for other satiety factors. However, our studies indicated
that circulating MIC-1/GDF15 levels were increased by only 10% from baseline values at two
hours post re-feeding. This modulation was small and delayed, and thus inconsistent with
what would be expected of a satiety factor. Further, these small changes in serum levels of
MIC-1/GDF15 in response to the meal are at least in part accounted for by its underlying diur-
nal variation pattern. Based on this data MIC-1/GDF15 secretion into the blood does not have
a pattern consistent with that of a satiety factor.
To investigate whether known satiety factors might modulate serum levels of MIC-1/
GDF15, we examined serum from subjects that had been infused with CCK-8, GLP-1, PYY1-
36 or PYY 3–36. Of these, only CCK-8 was associated with a significant alteration in MIC-1/
GDF15 serum levels relative to vehicle infusion. Indeed, when CCK was infused to mimic the
postprandial rise in its circulating levels, there was a 10% increase in serum levels of MIC-1/
GDF15 from its baseline at 120 minutes after commencement of infusion. This coincided with
the increase in serumMIC-1/GDF15 levels observed at 120 minutes after meal ingestion, sug-
gesting that a postprandial increase in circulating CCK-8 levels could have mediated the small
postprandial increase in circulating MIC-1/GDF15 levels. Thus, it is possible that the small
MIC-1/GDF15 level changes in response to meals, may be mediated in part by CCK-8.
In summary, our study suggests that MIC-1/GDF15 may play a role in human physiological
regulation of body weight, a finding that is consistent with data generated from mouse studies.
Also consistent with this, serum levels of MIC-1/GDF15 vary in diurnal pattern, similar to that
of leptin, a well-known regulator of long-term energy homeostasis. The absence of substantial
postprandial changes of MIC-1/GDF15 serum levels, distinct from its underlying diurnal varia-
tion in concentrations, suggest that MIC-1/GDF15 is unlikely to have significant satiety factor
like activity, but rather acts as a long-term regulator of energy homeostasis.
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